Mark A. Hurwitz
Impact in
-
- Intellectual Property and Patents
- Pharmacology top 2%
- Pharmaceutical industry and healthcare
Papers in
-
- Intellectual Property and Patents 3
-
- Pharmaceutical Economics and Policy 3
- Innovation Policy and R&D 1
- Co-authors
- Richard E. Caves (2 shared papers)Michael D. Whinston (1 shared paper)Peter Temin (1 shared paper)Ariel Pakes (1 shared paper)William Oh (1 shared paper)Philip W. Kantoff (2 shared papers)Jerome P. Richie (1 shared paper)Anthony V. D’Amico (1 shared paper)
- Journals
- International Journal of Radiation Oncology*Biology*Physics (1 paper)The Journal of Law and Economics (1 paper)Columbia Law Review (1 paper)RePEc: Research Papers in Economics (1 paper)
- Partner nations
- United States
In The Last Decade
Mark A. Hurwitz
4 papers receiving 416 citations
Peers
Comparison fields: 5 of 58
- Management of Technology and Innovation 158
- Pharmacology 166
- Economics and Econometrics 393
- Marketing 79
- Strategy and Management 54
Countries citing papers authored by Mark A. Hurwitz
This map shows the geographic impact of Mark A. Hurwitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Hurwitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Hurwitz more than expected).
Fields of papers citing papers by Mark A. Hurwitz
This network shows the impact of papers produced by Mark A. Hurwitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Hurwitz. The network helps show where Mark A. Hurwitz may publish in the future.
Co-authors
The 12 scholars most cited alongside Mark A. Hurwitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1991 | 281 | |
| 2 | 1988 | 178 | |
| 3 | Neoplasms of the Prostate | 2003 | 8 |
| 4 | 1991 | 4 | |
| 5 | 2000 | 1 |
About Mark A. Hurwitz
Mark A. Hurwitz is a scholar working on Management of Technology and Innovation, Economics and Econometrics, Pulmonary and Respiratory Medicine, Pharmacology and Radiation, having authored 5 papers that have together received 472 indexed citations. Recurring topics across this work include Intellectual Property and Patents (3 papers), Pharmaceutical Economics and Policy (3 papers), Prostate Cancer Treatment and Research (2 papers), Pharmaceutical industry and healthcare (2 papers), Prostate Cancer Diagnosis and Treatment (2 papers), Urologic and reproductive health conditions (1 paper), Innovation Policy and R&D (1 paper) and Advanced Radiotherapy Techniques (1 paper). The work is most often cited by research in Management of Technology and Innovation (158 citations), Pharmacology (166 citations), Economics and Econometrics (393 citations), Marketing (79 citations) and Strategy and Management (54 citations). Mark A. Hurwitz has collaborated with scholars based in United States. Frequent co-authors include Richard E. Caves, Michael D. Whinston, Peter Temin, Ariel Pakes, William Oh, Philip W. Kantoff, Jerome P. Richie, Anthony V. D’Amico, Clair J. Beard and Andrew A. Renshaw. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, The Journal of Law and Economics, Columbia Law Review and RePEc: Research Papers in Economics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.